The structural and functional complexity of the hu man interferon system has become increasingly evident. More than eight different alpha (leukocyte) interferons are expressed in induced human cells in culture. Many of these have been purified by a combination of methods, including high-performance liquid chromatography. Moreover, at least 12 different human leukocyte inter ferons have been cloned, and several have been effi ciently expressed in Escherichia coli and other orga nisms. The availability of purified species of leukocyte interferon, both natural and recombinant, has allowed structural work to be done, including amino acid se quence determinations, chemical modification studies, and the crystallization of one species. The purified ma terial has also been used for the production of mono clonal antibodies with various specificities that are proving invaluable in rapid assays and purification techniques. Testing of the purified species for their rel ative potency in antiviral, antiproliferative, and immu nomodulatory assays has begun to demonstrate the func tional uniqueness and diversity of the purified alpha interferons. Hybrid interferon genes have been synthe sized by splicing together parts of various cloned inter feron genes. The resulting hybrid proteins have been valuable in establishing structure/function relation ships. In several cases, the functional properties of the hybrid protein were novel and unpredicted from the properties of the parental molecules.
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Interferon was discovered by Isaacs and Lindenmann during an investigation of the phenomenon of viral interference, wherein infection by one virus produces resistance to subse quent infection by other, apparently unrelated viruses. Their work [1, 2] and that of others [3] demonstrated that cells could respond to challenge with a virus or with other substances (subsequently termed inducers) by producing a substance that could confer upon other cells resistance to subsequent viral attack. This substance, termed interferon, was characterized as a protein that had some species specificity, but that was fairly nonspecific in protecting against a wide range of viruses.
Since that time, the complexity of the system has increased as more interferon species within an organism have been rec ognized and characterized and biological effects have been documented [4] .
The chemical heterogeneity of the interferons has become increasingly evident (Table I ). It was found that interferons produced by different cell types were either stable or labile at pH 2. This lead to the designation of types I and II, respectively. ically distinguishable forms within the type I class. The type I and type II designations have now been superceded by a no· menclature based on antigenic properties and protein structure. Corresponding generalizations evolved that the different classes of interferons were produced by different cell types under the action of different inducers. These observations were the basis for the tripartite classification of leukocyte, fibroblast, and immune interferon. Because it is now recognized that some cells can simultaneously produce both leukocyte and fibroblast interferon, the classification based on producer-cell type has been considered inaccurate. Consequently, the human leuko· cyte, fibroblast, and immune interferons have been designated as a, /3, and I' classes, respectively. Subsequent work has demonstrated that there are at least 10 highly related human alpha interferons (IFN-a) each with characteristic chemical and biological properties and each encoded by a different gene. Thus far only a single protein species and gene have been isolated for the human /3 and I' interferons, although some evidence exists for heterogeneity of the /3 interferon [5] . There is some evidence that the a, /3, and I' classes do not encompass all the human interferons (reviewed in [5] ). However, these other species have not yet been clearly defined. Work on the function of the interferons has demonstrated that they are capable of numerous effects in biological systems (Table II) . Besides the antiviral effects, by which the interfer· ons were discovered and fu nctionally defined, the interferons are also potent inhibitors of growth and exhibit a number of immunomodulatory effects. This combination of activities has stimulated tremendous interest in their physiological roles and in their potential therapeutic applications, especially against viruses and tumors.
Considerable progress has been made in dissecting the bio chemistry of the antiviral response, particularly through the pathway involving the (2'-5')0Iigoadenylate synthetase (re viewed in [6] ). The product ofthis enzyme modulates the action of several enzymes, including the activation of a latent endo ribonuclease, ribonuclease L, which can degrade viral RNA. Other antiviral effects, probably distinct from this pathway, have been demonstrated, and it is unlikely that all viruses are inhibited via the same biochemical pathway. Recent work has also shown that at least 12 proteins are induced in cells treated with IFN-a, with an additional 12 proteins induced with IFN I' [7] . Despite such recent progress, our knowledge of the biochemistry of the antiviral response is at an early stage. Moreover, it is likely that the antiproliferative and immuno· modulatory effects of interferon are mediated through currently unknown biochemical pathways.
The ongoing expansion of biological and therapeutic work has been made possible by the availability of pure interferon. The purification and characterization of the leukocyte interfer ons from natural sources and the cloning and expression of these molecules in bacteria are allowing detailed investigations of the biological effects of the individual species and their interactions. This article summarizes recent advances in the purification and functional understanding of the human a (leukocyte) interferons and progress in defining the functional diversity of the individual molecular species. This article will emphasize the approaches and results obtained in our labora tory. T -lymphocytes + + 'Some evidence for additional !3 species has been presented. Genes for such species could contain introns [5] .
b Possible that minor species may be glycosylated. 
PURIFICATION AND PROPERTIES OF NATURAL LEUKOCYTE INTERFERONS
Since the lack of pure interferon was a serious drawback to both basic and clinical studies, purification of the interferons was early recognized as a critical task. While a large number of classical and novel techniques were attempted, the low abun dance of the molecule and some of its physicochemical prop erties prevented its purification and characterization.
Several developments allowed the successful purification of leukocyte interferon in our laboratory. These developments included a more rapid in vitro assay of antiviral activity, which took 16 hours rather than 3 days [8] , an efficient inducible system for the production of interferon, and a new purification scheme. The purification scheme was made possible by the use of high-performance liquid chromatography (HPLC), which had been modified for the analysis of amino acids, peptides, and proteins at the picomole level by a sensitive fluorescence assay developed by Sidney Udenfriend, Stanley Stein, and their colleagues in our Institute [9J.
The purification started with the induction of interferon in buffy coat leukocytes by Newcastle disease virus. Following several initial steps for the concentration and gross fractiona tion of the culture medium, the material was purified over a series of HPLC columns with results similar to those shown in Fig 1. Overall purification was about 60,000-to 80,000-fold from the initial incubation medium. These studies demonstra ted that human leukocyte interferon is actually a family of closely related proteins [10, 11] . Purification of leukocyte inter ferons by other workers also demonstrated the existence of multiple species [12,13,13aJ . This purification, the first re ported for any leukocyte interferon, produced a sufficient quan tity to allow the first chemical analysis and the first amino acid analysis of any interferon. The major problem behind this success was that the starting material came from buffy coats taken from 50 to 100 blood donors per week for several months.
With the demonstration that leukocytes from patients with chronic myelogenous leukemia (CML) were a rich source of interferon when induced, it was possible to use the same HPLC methodology for the purification of several species of leukocyte interferon from CML cells [14] . This purification permitted the amino acid analysis of several individual species [I1J. Moreover, it was then possible to look at the functional prop erties of the various natural species. The ability of the purified THE HUMAN INTERFERONS 1298 natural interferons to protect either bovine MDBK cells or human fibroblasts from killing by viruses was compared ( Table   III ). All purified species protected both bovine and human cells.
However, while there is only a four-fold variation in the pro tection of the bovine cells by the various leukocyte interferons, greater variation was observed in human cells. Specifically, two of the leukocyte species, 1'3 and 1'5, were considerably less active on human cells than were the others. This demonstrated the functional heterogeneity within the leukocyte interferon family. These results also contributed to the growing realization that interferons are not species-specific, but rather have character- istic patterns of activity on cells of different species. All these species exhibited antiproliferative activity [15] . Purification of multiple species was also accomplished with interferon produced by a continuous cell line, KG-I, which had been established from a patient with erythroleukemia [16] . Initial work in our laboratory demonstrated that KG-l was a good producer of interferon after proper growth and induction [17, 18] . Eventually, eight major species of human interferon were purified from these cells [19] . These also showed wide differences in potency on human cells, whereas all were quite active on bovine cells.
The purification of naturally induced human leukocyte in terferons conclusively established several concepts: (1) Multiple leukocyte interferon species can be induced simultaneously in cultured human cells. This immediately suggested the existence of multiple genes corresponding to each of these structurally distinct species. (2) These interferons are closely related, having similar, but not identical molecular weights, amino acid con tent, and tryptic maps. (3) Although all the species were active on both human and bovine cells, the relative specific activities, particularly on human cells, differed considerably. (4) No car bohydrate was detected on five of the purified species examined. This contradicted the previously accepted notion that all inter ferons were glycoproteins.
In addition to demonstrating that the various human leuko cyte interferons differ in their ability to confer antiviral pro tection on human cells, it was desirable to test their efficacy in other functional assays. Evinger et al [15] compared the ability of the purified species to inhibit cell multiplication of the human lymphoblastoid Daudi cell line (Table IV) . It was found that all the species exhibited antiproliferative activity on these cells, although their potencies differed. This supported the notion that the chemical differences of the leukocyte interferon TARLE III. S'pecific activities of human leukocyte interferons 
nomenclature is an internal laboratory notation denot ing peaks on HPLC columns. This nomenclature is unrelated to that of the three main classes of interferon. Data from [11] .
Vol. 83, No.1 Supplement species are reflected in functional differences. In comparing the potency of each leukocyte interferon species in the antiproli ferative assay with its potency in the antiviral assay, it was found that the ratios of antiproliferative-to-antiviral activity differed dramatically. A similar conclusion was drawn from experiments on the ability of the leukocyte interferons to stimulate natural killer cells (Table IV) . If the various effects of interferon-antiviral, antiproliferative, natural killer cell activation, etc.-were all mediated through the same biochem ical pathway, then it might be expected that the potency of a species in one assay would correlate with its potency in another assay. However, this was not observed. Thus the various effects must be mediated through different pathways. Where are the branchpoints in the pathways? How does a single interferon species generate different activities? These questions can be extended to the first molecular event-the binding of interferon to the cellular receptor. In the various assays on different human cell types, is the same cell surface receptor involved, or are there multiple receptors, each corresponding to a distinct biochemical pathway? Do different human cell types have different receptors, or is the same receptor able to trigger activities differentially following its activation? In summary, how is the cell able to respond uniquely to the various leukocyte interferons with resultant individual biochemical responses modulated to various degrees?
EXPRESSION AND CHARACTERIZATION OF HUMAN INTERFERONS PRODUCED IN BACTERIA
Although it was possible to purify sufficient quantities of interferons from induced cells in order to conduct the structural and functional studies described thus far, the purification from human cells was quite laborious. The techniques of recombi nant DNA technology presented the possibility of more easily producing large quantities of pure interferons and of getting at other questions concerning the gene structure and regulation of these proteins. Hence the cloning and expression of human C/ interferons was undertaken.
Plasmids containing cDNA copies of interferon-specific mRNA were constructed as follows [21] (Fig 2) : Leukocytes were stimulated by viruses for the production of interferon. The mRNA was extracted from these cells and was transcribed into DNA copies that were then ligated into bacterial plasmids. These were then used to transform E. coli. Individual trans formed colonies were screened for the presence of DNA com plementary to mRNA from interferon-producing cells, but not complementary to mRNA from cells that had not been induced for interferon production (Fig 3) . Positive colonies were then examined for the presence of interferon-specific sequences ( Fig   4) . The denatured plasmid DNA was attached covalently to DBM paper. RNA from interferon-producing cells was then allowed to hybridize to this DNA, and the paper was extensively washed to remove mRNA that was not complementary to the plasmid DNA. The bound mRNA was finally eluted from the paper and was injected into frog oocytes. Extracts from the frog oocytes were assayed for human interferon activity. The presence of such activity demonstrated that the mRNA that had been injected was specific for interferon and hence that the DNA to which it had hybridized on the filter paper had sequences corresponding to the interferon genes. When the nucleotide sequence of our first bacterial plasmid (p104) con taining the coding region for interferon was compared with the available amino acid sequence of purified 0' interferon, it was THE HUMAN INTERFERONS 131s discovered that only about 80% of the DNA sequence was in the plasmid [21] . Shortly before, Nagata et al [22] reported the cloning of human leukocyte (0') interferon [23] ; even earlier, Taniguchi et al [24] reported the cloning of human fibroblast ({3) interferon. This original plasmid (p104), while not itself containing the full-length copy of interferon cDNA, was instrumental in find ing other plasmids that had full-length copies of the a-inter feron mRNA [25] . A number of such plasmids containing cDNA from interferon-specific mRNA were identified [26] . From these sequences, the amino acid sequences of the proteins were predicted (Fig 5) . The sequences illustrate that the leukocyte interferons are a highly conserved family of proteins. In several cases it has been possible to correlate the natural and recom binant leukocyte interferons ( Table V) .
The original cDNA clones also provided a probe for identi fying DNA from the human genome containing sequences corresponding to the interferon genes. Thus far at least 12 distinct genomic sequences from a human embryonic DNA library in bacteriophage A have been found in our laboratory and others [25, [27] [28] [29] [30] . The existence of these distinct genomic sequences confirmed the deduction that the different leukocyte interferons are encoded by a closely related family of genes. Analysis of the genomic DNA also demonstrated that the genes lack introns found in most eukaryotic genes.
The bacterial plasmids containing the interferon cDNA were also used for the engineering of new plasmids that could direct the efficient production of interferon in the bacterial host ( Fig  6) . First, the cDNA sequence was excised from the bacterial plasmid by restriction endonuclease Pst!. Reflecting the general structure of eukaryotic mRNAs, the cDNA not only contained the information for the protein itself, but also was flanked on the 5' end by a sequence encoding the polypeptide leader sequence required for the export of the interferon from euLlr yotic cells. The coding sequence was also flanked on the 3' end by an untranslated sequence followed by a stretch of polyaden ylic acid. The interferon recombinant was reconstructed as shown in Fig 6. The result was that the sequence coding for the leader polypeptide was removed and an ATG initiator codon was added to the 5' end of the gene.
The gene was ligated into a new bacterial plasmid such that it was now flanked on the 5' end by the control region of the E. coli tryptophan operon (Fig 7) . This control region includes the RNA polymerase promoter region and a sequence specifying 'From [19] ; the a species from myeloblasts have not been purified to homogeneity.
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�""� ' � 5 0�b·P"""""�6 �7 0�b·P""""""" interferon. A eDNA recombinant plasmid for leukocyte A interferon was isolated. The PstI insert containing the complete eDNA sequence was excised. The three fragments shown above were isolated. The Sau:la-Auall fragments corresponds to amino acids 2 to l:i of the mature interferon. A synthetic DNA was synthesized that restored the TGT codon of Cysl, introduced a methionine initi ation codon (ATG) to the 5' side of the Cysl codon, and contained EcoRl and 8au:ia restriction sites. This was ligated to the 8au:3a-Avall fragment; the resultan t fragme nt was ligated to the 150-bp AvaII-BglIl and 670-bp HglII-PstI fragments . This final expression fragment contained the coding sequence for a mature leukocyte interferon with an additional methionine at the NH,-terminal end. This was ligated to the r;. coli tryptophan promoter-operator for high-efficiency expression in E. coli. the analysis of its three-dimensional structure by x-ray crys tallography. In addition, purified interferon was now available in large quantities for in vitro functional studies, for animal studies, and for human clinical trials.
MONOCLONAL ANTIBODIES TO INTERFERON
In experiments that were progressing simultaneously with the purification of the natural interferons, an array of mono clonal antibodies was produced in collaboration with Theophil Staehelin and his colleagues in Basel [3:3] . These monoclonal antibodies permitted the development of convenient solid phase radioimmunoassays for interferon [:34] , as well as the development of immunoaffinity columns for the rapid purifi cation of interferon from both natural and bacterial sources [35] . Additional possibilities for their use have arisen from the demonstration that many of these antibodies preferentially recognize native interferon rather than heat-denatured or chemically inactivated interferon [:36] .
INTERFERONS WITH NOVEL PROPERTIES
Plasmids containing interferon-specific DNA sequences have been utilized to create novel synthetic DNA genes by splicing parts of the natural genes together [37] [38] [39] (Fig 8) . These experiments demonstrated that the species specificity of the parental A and D interferons segregated with portions of the molecule. Similarly, when the parental and hybrid pro teins were tested for antiproliferative activity on human Daudi cells, their potency ranged over a factor of 5000-fold (Table   VII ). The ratios of antiproliferative to antiviral activity were seen to vary considerably (Table VII) . As discussed earlier, this ability of different leukocyte interferons to activate different cellular responses to various extents suggests that the biochem ical pathways of these responses diverge at some point, possibly as earlv as the interferon-receptor interaction. Finally, the finding ' that the A/D hybrids were active on mouse cells dem onstrated the potential of creating more diversity and possibly novel activities in the leukocyte interferons by manipulating the sequences by recombinant DNA technology. [40, 41] . We developed a simple purification procedure involving Blue-Sepharose chro matography followed by HPLC on octyl silica [42] . This pro cedure produced pure {3 interferon free of salts, solvents, and SDS. The specific activity of this material was 3 X 108 units per milligram of protein. The amino acid compositi ? n and t�e sequence of the first 19 amino acids were determmed. ThiS sequence confirmed and extended those reported earlier for the first 13 [43, 44] , and 10 residues [45] . Subsequently, this se quence was shown to be identical to that predicted from the nucleotide sequence of the cloned DNA.
The cloning and expression of the (3 interferon gene was accomplished in collaboration with Goeddel and coworkers [46) by procedures similar to those described for the cloning and expression of the a interferons. A cDNA library was can· structed with mRNA from human fibroblasts induced with polyinosinic· polycytidyic acid. A bacterial clone containing the fibroblast cDNA was identified by hybridization to radio I abe led cDNA prepared from 128 mRNA from induced fibroblasts as template for the reverse transcriptase and synthetic oligonu· cleotides predicted from the NH2-terminal amino acids as primers. The nucleotide sequence of a plasmid from the eDNA library was determined, allowing deduction of the total amino acid sequence of the fibroblast interferon and of its export signal sequence. An expression plasmid was t,!ten . constructed that permitted the synthesis in E. coli of 8 [23, 24, [46] [47] [48] , it seems that there is only a single major species of {3 interferon encoded by a single gene. Some evidence for molecular heterogeneity has been reported but not fully sub· stantiated [5] .
SUMMARY AND CONCLUSION
The human a (leukocyte) interferons are a family of closely related molecules, many of which can be simultaneously in duced. At least nine of these natural a interferons have been purified from several human sources. They have been chara<;
terized in terms of their species specificity in antiviral assays. In addition, their antiviral, antiproliferative, and natural killer cell stimulatory activities on human cells have been compared.
The variations in the absolute activities of the a interferons demonstrate that the chemical diversity is mirrored in func tional diversity.
A number of human IFN -a species have been cloned. These have been efficiently expressed in E. coli to produce purified interferon proteins. The large -scale production of genetically engineered interferon has made possible further physical and chemical characterization of the proteins, including the crys tallization of human leukocyte interferon A. This material has also been used fo r extensive animal and human clinical trials. The genes for the natural leukocyte interferon species have been genetically engineered to form hybrid genes coding for corresponding chimeric proteins. The hybrid proteins had some novel and unexpected characteristics, such as activity on mouse cells, which are generally insensitive to protection by human interferons.
The observation that the relative potencies of the leukocyte species, whether natural, recombinant, or hybrid, do not nec essarily correlate among the various functional assays suggests that the biological effects are differentially activated and hence must proceed along different biochemical pathways. The branchpoint for this differential activation of pathways is not known, but it could be as early as the recognition step by the cellular receptor, which itself could conceivably be a family of molecules.
The fact that the leukocyte interferon species are function ally distinct, despite their high degree of relatedness, as well as the fact that the genetic recombination of parts of the molecules may lead to new and unexpected functional changes, has several implications for the investigation of the therapeutic properties of interfe ron. First, for any application, each species will have to be tested for efficacy. Second, the usefulness of genetic engineering technology in this area not only might be in the production of large amounts of interferon, but also might be in the production of novel modified inte rferons that have such desirable combinations of properties as high specific potency for a particular application and low overall toxicity. The findin g of differential activation of biological effects makes this decou piing of desirable and undesirable properties theoretically rea sonable. However, any rational approach to the therapeutics of such a varied fa mily of molecules will depend on continuing experiments designed to identify the structural basis of the differential biological responses as well as experiments on the nature of the cellular receptor and the subsequent biochemical mechanisms involved.
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